The Clinical Research Core will provide centralized, quality controlled services for specimen processing, regulatory protocol management, development of Standard Operating Procedures, and limited specialized assay testing to support the research of Projects 1,2,3 and 4. The core will be responsible for the identification, recruitment, and phlebotomy of individuals to support U19 research objectives as well as the regulatory oversight of IRB protocols related to U19 research. Through the efforts of research associates and technicians, the core will be responsible for the processing and storage of the blood and serum samples obtained. The core will be responsible for a Quality Control Materials program to provide services related to Quality assurance of reagents and assays used in U19 research. This would include the establishment and optimization of standardized protocols, the development of a centralized comprehensive repository of positive control cell lines, the establishment of subject registry related to immunological characteristics of interest and the performance of established T cell assays to determine antigen specificity of PBMC samples and reagents. In addition, the clinical research core will provide a limited number of HLA typings for each of the proposed U19 projects.
The scope of the research encompassed by the four U19 investigator-initiated projects and the Technology Development Project would benefit not only from the shared cost of the resources of the proposed clinical core but also from the structure to standardize and disseminate new technologies that are developed within the individual projects.
|Mathew, Anuja (2017) Humanized mouse models to study human cell-mediated and humoral responses to dengue virus. Curr Opin Virol 25:76-80|
|Ramirez, Alejandro; Co, Mary; Mathew, Anuja (2016) CpG Improves Influenza Vaccine Efficacy in Young Adult but Not Aged Mice. PLoS One 11:e0150425|
|Townsley, E; O'Connor, G; Cosgrove, C et al. (2016) Interaction of a dengue virus NS1-derived peptide with the inhibitory receptor KIR3DL1 on natural killer cells. Clin Exp Immunol 183:419-30|
|Woda, Marcia; Friberg, Heather; Currier, Jeffrey R et al. (2016) Dynamics of Dengue Virus (DENV)-Specific B Cells in the Response to DENV Serotype 1 Infections, Using Flow Cytometry With Labeled Virions. J Infect Dis 214:1001-9|
|Tervo, Laura; Mäkelä, Satu; Syrjänen, Jaana et al. (2015) Smoking is associated with aggravated kidney injury in Puumala hantavirus-induced haemorrhagic fever with renal syndrome. Nephrol Dial Transplant 30:1693-8|
|Woda, Marcia; Mathew, Anuja (2015) Fluorescently labeled dengue viruses as probes to identify antigen-specific memory B cells by multiparametric flow cytometry. J Immunol Methods 416:167-77|
|Becerra-Artiles, Aniuska; Dominguez-Amorocho, Omar; Stern, Lawrence J et al. (2015) A Simple Proteomics-Based Approach to Identification of Immunodominant Antigens from a Complex Pathogen: Application to the CD4 T Cell Response against Human Herpesvirus 6B. PLoS One 10:e0142871|
|Jaiswal, Smita; Smith, Kenneth; Ramirez, Alejandro et al. (2015) Dengue virus infection induces broadly cross-reactive human IgM antibodies that recognize intact virions in humanized BLT-NSG mice. Exp Biol Med (Maywood) 240:67-78|
|Co, Mary Dawn T; Terajima, Masanori; Thomas, Stephen J et al. (2014) Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 Influenza in children. Viral Immunol 27:375-82|
|Terajima, Masanori; Co, Mary Dawn T; Ennis, Francis A (2014) Age and different influenza viruses. Lancet Infect Dis 14:101|
Showing the most recent 10 out of 109 publications